Kliniczne aspekty chorób układu moczowego: część 1 i 2 | Clinical Aspects of Urinary System Diseases: part 1 and 2

Tooltip .tooltip { position: relative; cursor: pointer; text-decoration: none; border-bottom: 1px dashed rgba(0, 0, 0, 0.6); } .tooltip::before { content: attr(data-tooltip); position: absolute; top: -40px; /* Trochę niżej nad słowem */ left: 50%; /* Wyśrodkowanie */ transform: translateX(-50%); background-color: rgba(255, 255, 255, 0.9); color: #333; padding: 6px 12px; border-radius: 8px; white-space: nowrap; opacity: 0; visibility: hidden; transition: opacity 0.3s ease, visibility 0.3s ease; font-family: ‘Arial’, sans-serif; font-size: 14px; box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1); z-index: 10; } .tooltip:hover::before { opacity: 1; visibility: visible; } document.addEventListener(‘DOMContentLoaded’, function () { const wordsToTooltip = { “Urinary Tract Infections”: “Zakażenia dróg moczowych”, “UTIs”: “ZUM”, “Bacterial infections”: “Infekcje bakteryjne”, “affected”: “dotknięty”, “Bacteria entering the urinary tract”: “Bakterie wnikające do dróg moczowych”, “Inflammation”: “Zapalenie”, “Infection”: “Infekcja”, “cystitis”: “Zapalenie pęcherza moczowego”, “urethritis”: “Zapalenie cewki moczowej”, “pyelonephritis”: “Odmiedniczkowe zapalenie nerek”, “Etiology and risk factors”: “Etiologia i czynniki ryzyka”, “Escherichia coli”: “Escherichia coli”, “Klebsiella”: “Klebsiella”, “Proteus”: “Proteus”, “Enterococcus”: “Enterococcus”, “Anatomical factors”: “Czynniki anatomiczne”, “Female anatomy”: “Budowa anatomiczna kobiet”, “Shorter urethra”: “Krótsza cewka moczowa”, “Susceptibility to infection”: “Podatność na infekcje”, “Sexual activity”: “Aktywność seksualna”, “Risk with intercourse”: “Ryzyko związane ze stosunkiem”, “Hygiene practices”: “Praktyki higieniczne”, “Improper wiping”: “Nieprawidłowe podcieranie”, “Excessive douching”: “Nadmierne irygacje”, “Urinary retention”: “Zatrzymanie moczu”, “Incomplete bladder emptying”: “Niecałkowite opróżnianie pęcherza moczowego”, “Diabetes”: “Cukrzyca”, “Immune compromise”: “Obniżona odporność”, “Glucose in urine”: “Glukoza w moczu”, “Catheter use”: “Używanie cewnika”, “Increased infection risk”: “Zwiększone ryzyko infekcji”, “Pathophysiology”: “Patofizjologia”, “Uropathogenic bacteria”: “Bakterie uropatogenne”, “Uroepithelium adherence”: “Przyczepność do urotelium”, “Fimbriae or pili”: “Fimbrie lub pilusy”, “Bacterial resistance to flushing”: “Odporność bakterii na wypłukiwanie”, “Inflammation of bladder wall”: “Zapalenie ściany pęcherza moczowego”, “Clinical manifestations”: “Objawy kliniczne”, “Dysuria”: “Bolesne oddawanie moczu”, “Increased frequency”: “Zwiększona częstotliwość oddawania moczu”, “Urgency to urinate”: “Nagła potrzeba oddania moczu”, “Nocturia”: “Nocne oddawanie moczu”, “Suprapubic pain”: “Ból nadłonowy”, “Hematuria”: “Krwiomocz”, “Cloudy urine”: “Mętny mocz”, “Foul-smelling urine”: “Nieprzyjemny zapach moczu”, “Diagnostic approach”: “Podejście diagnostyczne”, “Clinical evaluation”: “Ocena kliniczna”, “History and physical examination”: “Wywiad i badanie fizykalne”, “Urinalysis”: “Analiza moczu”, “Dipstick test”: “Test paskowy”, “Nitrites”: “Azotyny”, “Leukocyte esterase”: “Esteraza leukocytów”, “Microscopic urine examination”: “Badanie mikroskopowe moczu”, “Urine culture”: “Posiew moczu”, “Bacterial identification”: “Identyfikacja bakterii”, “Antibiotic sensitivity”: “Wrażliwość na antybiotyki”, “Imaging studies”: “Badania obrazowe”, “Ultrasound”: “Ultrasonografia”, “CT scan”: “Tomografia komputerowa”, “Structural abnormalities”: “Nieprawidłowości strukturalne”, “Treatment”: “Leczenie”, “Antibiotics”: “Antybiotyki”, “Nitrofurantoin”: “Nitrofurantoina”, “Fosfomycin”: “Fosfomycyna”, “Pain relief”: “Łagodzenie bólu”, “Phenazopyridine”: “Fenazopirydyna”, “Hydration”: “Nawodnienie”, “Fluid intake”: “Spożycie płynów”, “Follow-up for recurrent UTIs”: “Kontrola nawracających ZUM”, “Prophylactic antibiotics”: “Antybiotyki profilaktyczne”, “Complications of UTI”: “Powikłania ZUM”, “Pyelonephritis”: “Odmiedniczkowe zapalenie nerek”, “Fever”: “Gorączka”, “Chills”: “Dreszcze”, “Flank pain”: “Ból w boku”, “Recurrent infections”: “Nawracające infekcje”, “Chronic discomfort”: “Przewlekły dyskomfort”, “Kidney damage”: “Uszkodzenie nerek”, “Scarring”: “Powstawanie blizn”, “Impaired function”: “Zaburzona funkcja”, “Prognosis”: “Rokowanie”, “Cure rates”: “Wskaźniki wyleczenia”, “Recurrent infection risk”: “Ryzyko nawrotu infekcji”, “Trimethoprim-sulfamethoxazole”: “Trimetoprim-sulfametoksazol”, “Urinary Tract Obstruction”: “Zablokowanie dróg moczowych”, “Prerenal”: “Przednerkowy”, “Postrenal”: “Zanerkowy”, “Intrinsic”: “Nerkowy”, “Anorexia”: “Anoreksja”, “Itching”: “Swędzenie”, “Pruritus”: “Świąd”, “Cognitive changes”: “Zmiany poznawcze”, “Erythropoietin”: “Erytropoetyna”, “Fatigue”: “Zmęczenie”, “Erythropoiesis-Stimulating Agents”: “Leki stymulujące erytropoezę”, “Anemia”: “Niedokrwistość”, “CKD”: “Przewlekła choroba nerek (CKD)”, “End-stage renal disease”: “Schyłkowa niewydolność nerek”, “AKI”: “Ostra niewydolność nerek (AKI)”, “Acute Tubular Injury”: “Ostre uszkodzenie kanalików nerkowych”, “Glomerulonephritis”: “Kłębuszkowe zapalenie nerek”, “Interstitial Nephritis”: “Śródmiąższowe zapalenie nerek”, “Ischemia”: “Niedokrwienie”, “Nephrotoxic Agents”: “Czynniki nefrotoksyczne”, “Contrast Dye”: “Środek kontrastowy”, “Oliguria”: “Skąpomocz”, “Anuria”: “Bezmocz”, “Azotemia”: “Azotemia”, “Edema”: “Obrzęk”, “Hypertension”: “Nadciśnienie”, “Nausea”: “Nudności”, “Vomiting”: “Wymioty”, “Serum Creatinine”: “Kreatynina w surowicy”, “Blood Urea Nitrogen”: “Azot mocznika we krwi”, “Chronic Kidney Disease”: “Przewlekła choroba nerek”, “Comorbidities”: “Choroby współistniejące”, “Polycystic Kidney Disease”: “Wielotorbielowatość nerek”, “Obstructive Uropathy”: “Uropatia zaporowa”, “Non-Steroidal Anti-Inflammatory Drugs”: “Niesteroidowe leki przeciwzapalne (NLPZ)”, “Fibrosis”: “Zwłóknienie”, “Phosphate Binders”: “Środki wiążące fosforany”, “Cardiovascular Disease”: “Choroba sercowo-naczyniowa”, “Metabolic Acidosis”: “Kwasica metaboliczna” }; // Normalize keys in the dictionary const normalizedWordsToTooltip = {}; for (const [key, value] of Object.entries(wordsToTooltip)) { const cleanedKey = key.replace(/(.*?)/g, ”).trim(); // Remove anything in parentheses normalizedWordsToTooltip[cleanedKey.toLowerCase()] = value; } function processNode(node) { if (node.nodeType === Node.TEXT_NODE && node.nodeValue.trim()) { let content = node.nodeValue; // Regex to match only the main words (ignores parentheses) const regex = new RegExp( `b(${Object.keys(normalizedWordsToTooltip).join(‘|’)})b`, ‘gi’ ); if (regex.test(content)) { const wrapper = document.createElement(‘span’); wrapper.innerHTML = content.replace(regex, (match) => { const tooltip = normalizedWordsToTooltip[match.toLowerCase().trim()]; return `${match}`; }); node.replaceWith(wrapper); } } else if (node.nodeType === Node.ELEMENT_NODE) { Array.from(node.childNodes).forEach(processNode); } } document.querySelectorAll(‘body *:not(script):not(style)’).forEach((element) => { Array.from(element.childNodes).forEach(processNode); }); });Podświetlanie tekstu z notatkami body { margin: 0; padding: 0; font-family: Arial, sans-serif; } .highlight { background-color: #cce7ff; /* Highlight color without notes */ position: relative; display: inline; } .highlight.with-note { background-color: #ffeb3b; /* Highlight color with notes */ } .note-box { position: absolute; background-color: #f9f9f9; color: #333; font-size: 14px; line-height: 1.6; padding: 10px 15px; border: 1px solid #ddd; border-radius: 5px; box-shadow: 0 2px 5px rgba(0, 0, 0, 0.2); max-width: 250px; z-index: 1000; white-space: normal; text-align: left; display: none; /* Hidden by default */ } .note-controls { position: absolute; top: -30px; right: -30px; display: flex; gap: 10px; z-index: 10; opacity: 0; pointer-events: none; transition: opacity 0.3s; } .note-controls.visible { opacity: 1; pointer-events: all; } .note-controls span { cursor: pointer; background-color: gray; color: white; padding: 5px 10px; border-radius: 5px; font-size: 16px; font-weight: bold; } .note-controls span:hover { background-color: darkgray; } document.addEventListener(“DOMContentLoaded”, () => { /** * Checks if an element is a header. */ const isHeaderElement = (node) => { while (node) { if (node.nodeType === 1 && node.tagName.match(/^H[1-5]$/)) { return true; } node = node.parentNode; } return false; }; /** * Checks if an element is inside a table cell. */ const isInsideTable = (node) => { while (node) { if (node.tagName === “TD” || node.tagName === “TH”) { return node; } node = node.parentNode; } return null; }; /** * Checks if an element belongs to the same list item. */ const isWithinSameListItem = (selection) => { if (selection.rangeCount === 0) return false; const range = selection.getRangeAt(0); const startContainer = range.startContainer; const endContainer = range.endContainer; const getClosestListItem = (node) => { while (node) { if (node.nodeType === 1 && node.tagName === “LI”) { return node; } node = node.parentNode; } return null; }; const startListItem = getClosestListItem(startContainer); const endListItem = getClosestListItem(endContainer); // Ensure selection is within the same list item return startListItem === endListItem; }; /** * Validates the selection. * Ensures the selection is within a single header, table cell, or list item. */ const isSelectionValid = (selection) => { if (selection.rangeCount === 0) return false; const range = selection.getRangeAt(0); const startContainer = range.startContainer; const endContainer = range.endContainer; const startInHeader = isHeaderElement(startContainer); const endInHeader = isHeaderElement(endContainer); // Block selection spanning headers if (startInHeader !== endInHeader) { return false; } const startCell = isInsideTable(startContainer); const endCell = isInsideTable(endContainer); // Block selection spanning table cells if (startCell && endCell && startCell !== endCell) { return false; } // Block selection spanning multiple list items if (!isWithinSameListItem(selection)) { return false; } return true; }; /** * Highlights the selected text. */ const wrapTextWithHighlight = (range) => { const fragment = range.extractContents(); const highlight = document.createElement(“span”); highlight.className = “highlight”; highlight.appendChild(fragment); range.insertNode(highlight); const noteControls = document.createElement(“div”); noteControls.className = “note-controls visible”; const editNote = document.createElement(“span”); editNote.textContent = “✎”; editNote.title = “Edit note”; noteControls.appendChild(editNote); const removeHighlight = document.createElement(“span”); removeHighlight.textContent = “x”; removeHighlight.title = “Remove highlight”; noteControls.appendChild(removeHighlight); highlight.style.position = “relative”; highlight.appendChild(noteControls); let noteBox = null; const updateNotePosition = () => { const rect = highlight.getBoundingClientRect(); if (noteBox) { noteBox.style.top = `${rect.height}px`; noteBox.style.left = `${rect.width / 2}px`; } }; const hideControlsAndNoteAfterDelay = () => { setTimeout(() => { noteControls.classList.remove(“visible”); if (noteBox) noteBox.style.display = “none”; }, 3000); }; // Show controls for 3 seconds after highlighting hideControlsAndNoteAfterDelay(); highlight.addEventListener(“click”, () => { noteControls.classList.add(“visible”); if (noteBox) noteBox.style.display = “block”; hideControlsAndNoteAfterDelay(); }); editNote.addEventListener(“click”, () => { const noteText = prompt(“Add or edit a note:”, noteBox?.textContent || “”); if (noteText) { if (!noteBox) { noteBox = document.createElement(“div”); noteBox.className = “note-box”; highlight.appendChild(noteBox); } noteBox.textContent = noteText; noteBox.style.display = “block”; highlight.classList.add(“with-note”); updateNotePosition(); hideControlsAndNoteAfterDelay(); } }); removeHighlight.addEventListener(“click”, () => { const parent = highlight.parentNode; while (highlight.firstChild) { parent.insertBefore(highlight.firstChild, highlight); } parent.removeChild(highlight); if (noteBox) noteBox.remove(); }); }; /** * Handles the mouseup event to validate and apply highlighting. */ document.body.addEventListener(“mouseup”, () => { const selection = window.getSelection(); if (selection.rangeCount > 0 && selection.toString().trim()) { if (!isSelectionValid(selection)) { alert(“Zaznaczenie musi być w obrębie jednego akapitu, komórki tabeli lub punktu listy!”); selection.removeAllRanges(); return; } const range = selection.getRangeAt(0); wrapTextWithHighlight(range); selection.removeAllRanges(); } }); });
Szacowany czas lekcji: 38 minut
.lesson-duration-container { background-color: #f0f4f8; /* Szarawe tło dopasowane do reszty strony */ padding: 8px 15px; /* Wewnętrzny odstęp */ border-radius: 8px; /* Zaokrąglone rogi */ font-family: ‘Roboto’, Arial, sans-serif; /* Czcionka Roboto, jeśli dostępna */ font-size: 16px; /* Rozmiar tekstu */ color: #6c757d; /* Ciemny szary kolor tekstu */ display: inline-block; /* Wyświetlanie jako element blokowy */ margin-bottom: 20px; /* Odstęp na dole */ border: none; /* Bez obramowania */ } .lesson-duration-label { font-weight: 700; /* Pogrubienie dla etykiety */ color: #6c757d; /* Ciemny szary kolor dla etykiety */ margin-right: 5px; /* Odstęp od wartości */ } .lesson-duration-value { color: #6c757d; /* Ciemny szary kolor dla wartości */ font-weight: 700; /* Pogrubienie dla wartości */ }

Urinary Tract Infections (UTIs)

Urinary Tract Infections (UTIs) are among the most common bacterial infections, primarily affecting women, although they can occur in men and children as well. A UTI occurs when bacteria enter the urinary tract, leading to inflammation and infection. Commonly affected areas include the bladder (cystitis) and urethra (urethritis), but infections can also occur in the kidneys (pyelonephritis).

Etiology and Risk Factors

  • Bacterial Causes: The majority of UTIs are caused by Escherichia coli (E. coli), a bacterium normally found in the intestines. Other bacteria, such as Klebsiella, Proteus, and Enterococcus, can also cause infections.
  • Risk Factors:
    • Anatomical Factors: Female anatomy, such as a shorter urethra, increases susceptibility.
    • Sexual Activity: Increased risk associated with sexual intercourse.
    • Hygiene Practices: Improper wiping after bowel movements or excessive douching can introduce bacteria.
    • Urinary Retention: Inability to completely empty the bladder can promote bacterial growth.
    • Diabetes: Higher risk due to potential immune system compromise and glucose in urine.
    • Catheter Use: Increased risk of infection in individuals with urinary catheters.

Pathophysiology
UTIs typically occur when uropathogenic bacteria adhere to the uroepithelium in the urinary tract. This adhesion is facilitated by fimbriae or pili, allowing bacteria to resist flushing from the urinary stream. The infection leads to inflammation of the bladder wall, resulting in the classic symptoms of a UTI.

Clinical Manifestations

  • Lower Urinary Tract Symptoms:
    • Dysuria: A burning sensation during urination.
    • Increased Frequency: Frequent urination with little output.
    • Urgency: A strong, persistent urge to urinate.
    • Nocturia: Increased urination during the night.
  • Other Symptoms:
    • Suprapubic Pain: Discomfort or pressure in the lower abdomen.
    • Hematuria: Blood in the urine, which may appear pink or red.
    • Cloudy or Foul-Smelling Urine: Indicative of infection.

Diagnostic Approach

  • Clinical Evaluation: A thorough history and physical examination to assess symptoms and risk factors.
  • Urinalysis: A dipstick test to check for nitrites, leukocyte esterase, and blood, along with microscopic examination of urine.
  • Urine Culture: A definitive test to identify the specific bacteria causing the infection and determine antibiotic sensitivity.
  • Imaging Studies: Ultrasound or CT scan may be necessary in recurrent cases to identify any structural abnormalities.

Treatment

  • Antibiotics: The first-line treatment for uncomplicated UTIs includes:
    • Trimethoprim-sulfamethoxazole (TMP-SMX).
    • Nitrofurantoin.
    • Fosfomycin.
  • Pain Relief: Phenazopyridine can help alleviate pain and discomfort associated with dysuria.
  • Hydration: Increasing fluid intake can help flush out bacteria from the urinary tract.
  • Follow-Up: For recurrent UTIs, further evaluation and possibly prophylactic antibiotics may be warranted.

Complications

  • Pyelonephritis: A more severe infection of the kidneys that can lead to systemic symptoms such as fever, chills, and flank pain.
  • Recurrent Infections: Women with recurrent UTIs may experience multiple infections within a year, leading to chronic discomfort.
  • Kidney Damage: Untreated or severe infections can lead to scarring and impaired kidney function.

Prognosis

  • Generally Favorable: Most UTIs resolve within 1 to 3 days with appropriate antibiotic treatment, with cure rates exceeding 90%. However, approximately 20-30% of women may experience recurrent infections within six months, highlighting the need for ongoing monitoring and management.

Acute Kidney Injury (AKI)

Acute Kidney Injury (AKI), formerly known as acute renal failure, is a rapid decline in kidney function, characterized by the accumulation of waste products in the blood and an imbalance in fluids and electrolytes. AKI can occur over hours to days and is often reversible if detected and treated early. It can be classified into three main categories: prerenal, intrinsic, and postrenal, based on the underlying cause of the kidney dysfunction.

Etiology and Risk Factors

  • Prerenal Causes: These are due to decreased blood flow to the kidneys, leading to reduced glomerular filtration rate (GFR). Common causes include:
    • Hypovolemia: Dehydration, significant blood loss, or fluid loss due to diarrhea or vomiting.
    • Decreased Cardiac Output: Conditions such as heart failure or shock.
    • Renal Artery Stenosis: Narrowing of the renal arteries reduces blood supply to the kidneys.
  • Intrinsic Causes: These arise from direct damage to the renal parenchyma and can include:
    • Acute Tubular Injury (ATI): Often due to ischemia or nephrotoxic agents (e.g., certain medications, contrast dye).
    • Glomerulonephritis: Inflammation of the glomeruli can lead to AKI.
    • Interstitial Nephritis: An inflammatory response often related to drugs or infections.
  • Postrenal Causes: Result from obstruction in the urinary tract, leading to increased pressure in the kidneys. Causes include:
    • Urinary Tract Obstruction: Kidney stones, tumors, or enlarged prostate causing blockage of urine flow.

Pathophysiology

AKI involves a rapid decrease in kidney function, leading to the retention of nitrogenous waste products (e.g., urea, creatinine) in the blood. This can result from decreased perfusion (prerenal), direct damage to the kidney tissue (intrinsic), or obstruction (postrenal). The reduction in GFR impacts the kidneys’ ability to regulate fluid and electrolyte balance, leading to complications such as fluid overload, electrolyte imbalances (e.g., hyperkalemia), and metabolic acidosis.

Clinical Manifestations

  • Oliguria or Anuria: Reduced urine output, with less than 400 mL/day considered oliguria and less than 100 mL/day anuria.
  • Azotemia: Elevated levels of urea and creatinine in the blood.
  • Fluid Overload: Symptoms may include swelling (edema), shortness of breath, and hypertension.
  • Electrolyte Imbalances: Hyperkalemia (high potassium levels) can lead to muscle weakness and cardiac arrhythmias.
  • Nausea and Vomiting: Due to the accumulation of waste products.

Diagnostic Approach

  • Clinical Evaluation: A detailed history and physical examination to assess symptoms and risk factors.
  • Laboratory Tests:
    • Serum Creatinine and Blood Urea Nitrogen (BUN): Elevated levels indicate reduced kidney function.
    • Electrolyte Panel: To evaluate for imbalances such as hyperkalemia.
    • Urinalysis: Can provide clues to the cause, such as the presence of casts or blood.
  • Imaging Studies: Ultrasound or CT scans may be performed to identify obstruction or structural abnormalities.

Treatment

  • Supportive Care: Managing fluid balance, electrolyte levels, and blood pressure. Diuretics may be used to manage fluid overload.
  • Addressing the Underlying Cause:
    • Prerenal: Volume resuscitation with fluids if due to hypovolemia.
    • Intrinsic: Discontinuation of nephrotoxic medications, treating underlying conditions (e.g., glomerulonephritis).
    • Postrenal: Relieving obstruction, which may involve catheterization or surgical intervention.
  • Dialysis: May be required in severe cases where kidney function does not improve, especially if there are life-threatening electrolyte imbalances or fluid overload.

Complications

  • Chronic Kidney Disease (CKD): Some patients may progress to CKD if AKI is not resolved or is recurrent.
  • Electrolyte Imbalances: Persistent issues, particularly hyperkalemia and metabolic acidosis, can have serious consequences.
  • Infection: Increased susceptibility due to compromised renal function and potential need for invasive procedures.
  • Mortality: The mortality rate for AKI varies based on the underlying cause and the patient’s overall health, ranging from 15% to over 50% in severe cases, particularly in those with multiple comorbidities.

Prognosis

  • Variable Outcomes: The prognosis for AKI can vary widely. Many patients recover kidney function within days to weeks with appropriate treatment. However, the risk of developing chronic kidney disease increases with the severity of AKI and the presence of underlying conditions. Approximately 30-50% of individuals who experience AKI will have persistent renal impairment, emphasizing the importance of early detection and management.

Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) is a progressive condition characterized by a gradual loss of kidney function over months or years. It is defined by a decrease in the glomerular filtration rate (GFR) to less than 60 mL/min/1.73 m² for three months or more, or by the presence of kidney damage markers such as proteinuria or hematuria. CKD is a significant public health concern due to its high prevalence and association with increased morbidity and mortality.

Etiology and Risk Factors

  • Diabetes Mellitus: The leading cause of CKD, accounting for approximately 40% of cases. Chronic hyperglycemia damages the blood vessels in the kidneys.
  • Hypertension: Uncontrolled high blood pressure can damage the kidneys over time, contributing to CKD development.
  • Glomerulonephritis: Inflammation of the kidney’s filtering units can lead to kidney damage and loss of function.
  • Polycystic Kidney Disease: A genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to kidney failure.
  • Obstructive Uropathy: Conditions that cause blockage of urine flow can lead to kidney damage.
  • Other Factors: Age, family history of kidney disease, cardiovascular disease, and certain medications (e.g., non-steroidal anti-inflammatory drugs) increase the risk.

Pathophysiology

CKD is characterized by progressive nephron loss and compensatory hyperfiltration in remaining nephrons, which eventually leads to further nephron injury and fibrosis. As kidney function declines, waste products accumulate in the blood, leading to metabolic imbalances, hypertension, and cardiovascular complications. The disease can progress through various stages, with increasing severity of symptoms and complications as GFR decreases.

Clinical Manifestations

  • Early Stages: Many individuals are asymptomatic in the early stages. Mild symptoms may include fatigue, weakness, and decreased appetite.
  • Advanced Stages: As CKD progresses, symptoms can include:
    • Edema: Swelling in the legs, ankles, or face due to fluid retention.
    • Uremic Symptoms: Nausea, vomiting, anorexia, itching (pruritus), and cognitive changes.
    • Anemia: Due to decreased erythropoietin production, leading to fatigue and weakness.
    • Bone Disease: Mineral and bone disorders due to imbalances in calcium, phosphate, and vitamin D metabolism.

Diagnostic Approach

  • Laboratory Tests:
    • Serum Creatinine and BUN: Elevated levels indicate reduced kidney function.
    • Glomerular Filtration Rate (GFR): Calculated using serum creatinine, age, gender, and race.
    • Urinalysis: Presence of protein, blood, or abnormal cells in the urine.
    • Electrolyte Panel: To assess for imbalances, particularly potassium and phosphate.
  • Imaging Studies: Ultrasound may be used to evaluate kidney size, structure, and any obstruction.

Treatment

  • Management of Underlying Conditions:
    • Diabetes Management: Tight glycemic control can slow CKD progression.
    • Blood Pressure Control: ACE inhibitors or angiotensin II receptor blockers (ARBs) are often used to manage hypertension and provide renal protection.
  • Dietary Modifications:
    • Protein Restriction: Reducing dietary protein intake may help slow disease progression in some patients.
    • Sodium and Fluid Restriction: To manage blood pressure and fluid retention.
  • Medications:
    • Phosphate Binders: To manage hyperphosphatemia.
    • Erythropoiesis-Stimulating Agents (ESAs): To treat anemia.
  • Dialysis or Transplantation: Advanced CKD (stage 5) may require renal replacement therapy, either through dialysis or kidney transplantation.

Complications

  • Cardiovascular Disease: CKD significantly increases the risk of heart disease, stroke, and heart failure.
  • Anemia: Often requires treatment with iron supplementation or ESAs.
  • Bone Mineral Disorders: Can lead to osteoporosis and increased fracture risk.
  • Metabolic Acidosis: Resulting from impaired kidney function, which can affect overall health.

Prognosis

  • Variable Outcomes: The prognosis for CKD varies based on the underlying cause, stage of disease, and effectiveness of management. Approximately 10-15% of patients with CKD progress to end-stage renal disease (ESRD) requiring dialysis or transplantation.